<DOC>
	<DOCNO>NCT01947036</DOCNO>
	<brief_summary>The study aim establish whether defect immune cell function share across multiple autoimmune diseases whether problem match similar gene cell .</brief_summary>
	<brief_title>T B Cell Responses Autoimmune Diseases</brief_title>
	<detailed_description>This non-randomized , multi-center clinical research study . Subjects healthy confirm suspected diagnosis type 1diabetes , multiple sclerosis , psoriasis , Crohn 's disease , rheumatoid arthritis ask donate blood sample . No follow-ups plan . Investigators : - evaluate immune cell subject enrol study match difference type immune cell know cause autoimmune diseases - investigate particular disease pathway : IL23R signal cascade .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Subject subject 's parent legal guardian provide write informed consent For healthy donor : Healthy individual 18 60 year age , inclusive For subject autoimmune disease : 1 . Adults 18 60 year , inclusive , diagnose suspect one follow five disease : adult form rheumatoid arthritis ( RA ) , type 1 diabetes ( T1D , T1DM ) , multiple sclerosis ( MS ) , Crohn 's disease ( CD ) , Psoriasis ( Ps ) 2 . Or Children 8 year 18 year inclusive , diagnose suspect type 1 diabetes ( TID ) Crohn 's disease ( CD ) 3 . Treatment naïve except prednisone ( equivalent corticosteroid ) &lt; \=10mg/day 4 . For subject diagnose type 1 diabetes : 1 . Clinical diagnosis suspect diagnosis T1D 2 . Positive per standard clinical titer level antiinsulin antibody within 10 day diagnosis ( newonset T1D ) ; otherwise one follow antibodiesantiGAD65 , antiICA512/IA2 antiZnT8 3 . Minimum body weight 17kg ( ≥37.5 pound ) 4 . Disease duration within 1 year 5 . For subject diagnose multiple sclerosis : a. EDSS ( Expanded Disability Status Scale ) 05 b . Diagnosis suspect diagnosis MS per Dr. Polman et al . Annals Neurology 2010 c. Disease duration within 1 year 6 . For subject diagnose rheumatoid arthritis ( RA ) : . Diagnosis suspect diagnosis RA ( 2010 ACR criterion ) b. AntiCCP antibody positive c. Disease duration within 1 year 7 . For subject diagnose Crohn 's disease : . Clinical diagnosis suspect diagnosis Crohn 's confirm endoscopy b . Disease duration within 1 year c. Minimum body weight 17 kg ( ≥37.5 pound ) 8 . For subject diagnose psoriasis : 1 . Psoriasis diagnosis dermatologist 2 . Disease duration within 1 year 3 . At least two psoriatic plaque single plaque occupy least 1 % total body surface outside scalp 1 . For healthy donor : . Individuals unable unwilling donate blood sample b . Individuals selfreported chronic metabolic diseases type 2 diabetes , impair glucose tolerance morbid obesity c. Individuals selfreported acute infection ( respiratory others ) chronic infection ( HIV , hepatitis B C ) d. Individuals selfreported immunemediated disease multiple sclerosis , type 1 diabetes , primary immunodeficiency e. Individuals selfreported current prior history malignancy f. Individuals currently pregnant ( selfreport ) g. Corticosteroid therapy equivalent &gt; /= 10 mg/day prednisone within last 4 week h. Immunosuppressive therapy time prior enrollment ( Cyclophosphamide , Mitoxantrone , Imuran , Cellcept , Methotrexate , Rituximab , Alemtuzumab ) 2 . For subject autoimmune disease : . Pregnant patient b. Pediatric patient unable donate least 51 mL blood per NIH guideline ( 5 mL/kg single day 9.5 mL/kg 8 week period ) c. Patients current substance abuse alcoholism ( selfreport ) d. Patients diagnose one autoimmune and/or inflammatory disease , exception asthma permissible e. Corticosteroid therapy equivalent &gt; 10 mg/day prednisone within last 4 week f. Immunomodulatory therapy within last 12 month ( Interferon , Glatiramer Acetate , Natalizumab , Fingolimod ) g. Immunosuppressive medication time prior enrollment ( Cyclophosphamide , Mitoxantrone , Imuran , Cellcept , Methotrexate , Rituximab , Alemtuzumab ) h. Any prior current Antitumor necrosis factor ( antiTNF ) treatment . Any prior current use experimental drug test Phase I , II , III clinical trial 3 . Diagnosis ulcerative colitis indeterminate colitis 4 . Pustular psoriasis , isolated palmoplantar psoriasis , isolated inverse psoriasis isolate sebopsoriasis .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>autoimmune disease</keyword>
	<keyword>immune-mediated disease</keyword>
	<keyword>T B cell immunophenotype</keyword>
	<keyword>IL23 signal</keyword>
	<keyword>genetic risk variant</keyword>
</DOC>